BioInvent International has carried out a directed issue raising approximately SEK 85 million through an accelerated book building process.
BioInvent International AB is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The company has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. BioInvent International’s shares are listed on Nasdaq Stockholm.
BioInvent International was advised by Mannheimer Swartling in the transaction.